Implementation and implications for polygenic risk scores in healthcare

被引:44
|
作者
Slunecka, John L. [1 ]
van der Zee, Matthijs D. [2 ]
Beck, Jeffrey J. [1 ]
Johnson, Brandon N. [1 ]
Finnicum, Casey T. [1 ]
Pool, Rene [2 ]
Hottenga, Jouke-Jan [2 ]
de Geus, Eco J. C. [2 ]
Ehli, Erik A. [1 ]
机构
[1] Avera McKennan & Univ Hlth Ctr, Avera Inst Human Genet, Sioux Falls, SD 57105 USA
[2] Vrije Univ Amsterdam, Dept Biol Psychol, Netherlands Twin Register, Amsterdam, Netherlands
关键词
Polygenic risk score; PRS; Clinical genetics; Genetic risk; Risk stratification; Public health; GENOME-WIDE ASSOCIATION; GENETIC RISK; FAMILY-HISTORY; CARDIOVASCULAR-DISEASE; TASK-FORCE; CANCER; ACCURACY; POPULATION; PREVENTION; DEPRESSION;
D O I
10.1186/s40246-021-00339-y
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Increasing amounts of genetic data have led to the development of polygenic risk scores (PRSs) for a variety of diseases. These scores, built from the summary statistics of genome-wide association studies (GWASs), are able to stratify individuals based on their genetic risk of developing various common diseases and could potentially be used to optimize the use of screening and preventative treatments and improve personalized care for patients. Many challenges are yet to be overcome, including PRS validation, healthcare professional and patient education, and healthcare systems integration. Ethical challenges are also present in how this information is used and the current lack of diverse populations with PRSs available. In this review, we discuss the topics above and cover the nature of PRSs, visualization schemes, and how PRSs can be improved. With these tools on the horizon for multiple diseases, scientists, clinicians, health systems, regulatory bodies, and the public should discuss the uses, benefits, and potential risks of PRSs.
引用
收藏
页数:18
相关论文
共 50 条
  • [31] Polygenic Risk Scores for Subtyping of Schizophrenia
    Chen, Jingchun
    Mize, Travis
    Wu, Jain-Shing
    Hong, Elliot
    Nimgaonkar, Vishwajit
    Kendler, Kenneth S.
    Allen, Daniel
    Oh, Edwin
    Netski, Alison
    Chen, Xiangning
    SCHIZOPHRENIA RESEARCH AND TREATMENT, 2020, 2020
  • [32] Polygenic Risk Scores in Human Disease
    Maamari, Dimitri J.
    Abou-Karam, Roukoz
    Fahed, Akl C.
    CLINICAL CHEMISTRY, 2025, 71 (01) : 69 - 76
  • [33] Polygenic risk scores and rheumatic diseases
    Matthew A. Brown
    Zhixiu Li
    中华医学杂志英文版, 2021, 134 (21) : 2521 - 2524
  • [34] Polygenic risk scores for CARDINAL study
    Adebamowo, Clement A.
    Adeyemo, Adebowale
    Ashaye, Adeyinka
    Akpa, Onoja M.
    Chikowore, Tinashe
    Choudhury, Ananyo
    Fakim, Yasmina J.
    Fatumo, Segun
    Hanchard, Neil
    Hauser, Michael
    Mitchell, Braxton
    Mulder, Nicola
    Ofori-Acquah, Solomon F.
    Owolabi, Mayowa
    Ramsay, Michele
    Tayo, Bamidele
    VasanthKumar, Archana Bhavani
    Zhang, Yuji
    Adebamowo, Sally N.
    NATURE GENETICS, 2022, 54 (05) : 527 - 530
  • [35] Polygenic Risk Scores: What Are They Good For?
    Zheutlin, Amanda B.
    Ross, David A.
    BIOLOGICAL PSYCHIATRY, 2018, 83 (11) : E51 - E53
  • [36] Polygenic Risk Scores in Breast Cancer
    Lida A. Mina
    Banu Arun
    Current Breast Cancer Reports, 2019, 11 : 117 - 122
  • [37] Polygenic risk scores: a biased prediction?
    De La Vega, Francisco M.
    Bustamante, Carlos D.
    GENOME MEDICINE, 2018, 10
  • [38] Polygenic Risk Scores for Breast Cancer
    Demarest, Kaitlin
    Shah, Payal D.
    CURRENT BREAST CANCER REPORTS, 2024, 16 (02) : 269 - 277
  • [39] Polygenic risk scores and rheumatic diseases
    Brown, Matthew A.
    Li, Zhixiu
    CHINESE MEDICAL JOURNAL, 2021, 134 (21) : 2521 - 2524
  • [40] THEORY AND APPLICATIONS OF POLYGENIC RISK SCORES
    Dudbridge, Frank
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S109 - S109